open access

Vol 20, No 2 (2013)
Original articles
Published online: 2013-04-05
Get Citation

Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients

Marek Postula, Piotr K. Janicki, Marek Rosiak, Adam Przybylkowski, Agnieszka Kaplon-Cieslicka, Tomasz Grygorowicz, Ewa Trzepla, Krzysztof J. Filipiak, Andrzej Czlonkowski, Grzegorz Opolski
DOI: 10.5603/CJ.2013.0030
·
Cardiol J 2013;20(2):170-177.

open access

Vol 20, No 2 (2013)
Original articles
Published online: 2013-04-05

Abstract

Background: The objective of this study was to investigate the association between plasma
concentrations of salicylic acid (SA) and other minor acetylsalicylic acid (ASA) metabolites
and high on ASA platelet reactivity assessed with different methods in type 2 diabetic patients
(T2DM).

Methods: Study cohort consisted of 293 T2DM patients on chronic ASA therapy. Platelet
function inhibition was analyzed using measurements of serum thromboxane B2 (S-TxB2),
VerifyNow Aspirin and Platelet Function Analyzer (PFA)-100 assays. The concentration of ASA
metabolites in plasma was measured with a high-performance liquid chromatography (HPLC).

Results: In logistic regression analysis both ASA dose/kg of body weight and plasma SA
concentration were found to be predictive of S-TxB2 concentrations above 0.72 ng/mL cut-off
point (OR 16.9, 95% CI 2.29–125.8, p = 0.006 and OR 5.34, 95% CI 2.67–10.68, p < 0.001,
respectively). When using the VerifyNow Aspirin Assay, the concentrations of SA were signifi -
cantly lower (p = 0.007) in the group with high on ASA platelet reactivity when compared with
the group with normal on ASA platelet reactivity. In logistic regression analysis plasma SA
concentration was found to be predictive of VerifyNow Aspirin Reaction Units (ARU) ≥ 550
(OR 3.86, 95% CI 1.86–8.00, p < 0.001).

Conclusions: Our study suggests that disturbances of pharmacokinetic mechanisms might
contribute to lower plasma SA levels, and subsequently incomplete inhibition of thromboxane A2
synthesis as measured with S-TxB2 concentrations and increased platelet reactivity measured
with VerifyNow in T2DM patients.

Abstract

Background: The objective of this study was to investigate the association between plasma
concentrations of salicylic acid (SA) and other minor acetylsalicylic acid (ASA) metabolites
and high on ASA platelet reactivity assessed with different methods in type 2 diabetic patients
(T2DM).

Methods: Study cohort consisted of 293 T2DM patients on chronic ASA therapy. Platelet
function inhibition was analyzed using measurements of serum thromboxane B2 (S-TxB2),
VerifyNow Aspirin and Platelet Function Analyzer (PFA)-100 assays. The concentration of ASA
metabolites in plasma was measured with a high-performance liquid chromatography (HPLC).

Results: In logistic regression analysis both ASA dose/kg of body weight and plasma SA
concentration were found to be predictive of S-TxB2 concentrations above 0.72 ng/mL cut-off
point (OR 16.9, 95% CI 2.29–125.8, p = 0.006 and OR 5.34, 95% CI 2.67–10.68, p < 0.001,
respectively). When using the VerifyNow Aspirin Assay, the concentrations of SA were signifi -
cantly lower (p = 0.007) in the group with high on ASA platelet reactivity when compared with
the group with normal on ASA platelet reactivity. In logistic regression analysis plasma SA
concentration was found to be predictive of VerifyNow Aspirin Reaction Units (ARU) ≥ 550
(OR 3.86, 95% CI 1.86–8.00, p < 0.001).

Conclusions: Our study suggests that disturbances of pharmacokinetic mechanisms might
contribute to lower plasma SA levels, and subsequently incomplete inhibition of thromboxane A2
synthesis as measured with S-TxB2 concentrations and increased platelet reactivity measured
with VerifyNow in T2DM patients.
Get Citation

Keywords

aspirin, diabetes, salicylic acid, platelet reactivity, platelet function testing

About this article
Title

Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients

Journal

Cardiology Journal

Issue

Vol 20, No 2 (2013)

Pages

170-177

Published online

2013-04-05

DOI

10.5603/CJ.2013.0030

Bibliographic record

Cardiol J 2013;20(2):170-177.

Keywords

aspirin
diabetes
salicylic acid
platelet reactivity
platelet function testing

Authors

Marek Postula
Piotr K. Janicki
Marek Rosiak
Adam Przybylkowski
Agnieszka Kaplon-Cieslicka
Tomasz Grygorowicz
Ewa Trzepla
Krzysztof J. Filipiak
Andrzej Czlonkowski
Grzegorz Opolski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl